The current and future landscape of urinary thromboxane testing to evaluate atherothrombotic risk.

Sean-Xavier Neath, MD, PhD, FACEP,1 John L. Jefferies, MD, MPH, FAAP, FACC, FAHA,2 Jeffrey S. Berger, MD, MS, FAHA, FACC,3 Alan H.B. Wu, PhD,4 Joseph P. McConnell, PhD, DABCC,5 Jeffrey L. Boone, MS, MD,6 Peter A. McCullough, MD, MPH, FACC, FACP, FCCP, FAHA, FNKF,7 Robert L. Jesse, MD, PhD,8 Alan S. Maisel, MD9 1Department of Emergency Medicine, University of California, San Diego, San Diego, CA; 2Advanced Heart Failure and Cardiomyopathy Services, Pediatric Cardiology and Adult Cardiovascular Diseases, and Division of Human Genetics, The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 3Department of Medicine, and Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY; 4Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA; 5Health Diagnostic Laboratory, Richmond, VA; 6Boone Heart Institute, Denver, CO; 7Baylor Heart and Vascular Institute, Dallas, TX; 8Departments of Internal Medicine and Cardiology, Virginia Commonwealth University Health System, Richmond, VA, and Veterans Health Administration, Department of Veterans Affairs, Washington, DC; 9Department of Medicine, Division of Cardiovascular Medicine, University of California, San Diego and Director, Coronary Care Unit and Heart Failure Program, Veterans Affairs San Diego Healthcare System, San Diego, CA